Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration
REDWOOD CITY, CA--(Marketwired - Sep 19, 2017) - Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age- …